Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Analyst Rating of 'Moderate Buy'

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has recently been given an average rating of "Moderate Buy" by analysts from five different research firms. According to MarketBeat Ratings, this rating indicates a generally positive outlook for the company. Among these analysts, two have assigned a hold rating to the stock, while three have given it a buy rating. The average target price for Inovio Pharmaceuticals over the next year is estimated at $38.00, based on analysts' evaluations.

Inovio Pharmaceuticals has been the subject of various recent research notes. For instance, on November 15th, Royal Bank of Canada downgraded its price target for Inovio shares from $7.00 to $6.00, maintaining a "sector perform" rating. Shortly after, on November 18th, HC Wainwright reduced its price target from $12.00 to $5.00 and set a "neutral" rating for the company. On the same day, Oppenheimer lowered their target price from $33.00 to $15.00 while keeping an "outperform" rating on Inovio.

Recent Price Performance of Inovio Pharmaceuticals

As of Thursday, shares of Inovio Pharmaceuticals opened at $4.03. The stock has seen a fifty-two week low of $3.85, with a peak of $14.75 during the same period. Currently, Inovio has a market capitalization of $105.05 million, with a price-to-earnings ratio of -1.16 and a beta value of 0.75. The company's fifty-day moving average stands at $4.99, while the two-hundred-day moving average is at $7.23.

Institutional Investment Trends

In recent months, hedge funds have shown increased interest in Inovio Pharmaceuticals, either by raising or lowering their stakes in the company. Notably, Barclays PLC significantly boosted its ownership by 282.6% in the third quarter, acquiring an additional 25,116 shares, bringing its total to 34,003 shares valued at $197,000. Meanwhile, Geode Capital Management LLC increased its holdings by 6.7%, now owning 621,631 shares valued at $3,594,000 after acquiring another 38,833 shares. Additionally, Wellington Management Group LLP entered a new stake worth approximately $379,000, and State Street Corp increased its share count by 11.7% during the third quarter, now holding 490,662 shares valued at $2,836,000. Overall, institutional investors own about 26.79% of Inovio Pharmaceuticals' stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines for treating diseases such as human papillomavirus (HPV), various forms of cancer, and infectious diseases. The company employs a unique platform that utilizes precisely designed SynCon technologies to optimize the DNA sequence of target antigens and facilitates the delivery of DNA plasmids through CELLECTRA smart devices.

Inovio, Pharmaceuticals, Stocks